Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine
| Autor: | Jan Lewis Brandes, Nancy C. Santanello, Filippa Guerra, Denise R Boyle, Norman R. Bohidar, Lixia Wang, Franck Skobieranda, Andrea H Kolodny, Stephen D. Silberstein, Elizabeth Loder, Lisa Johnson-Pratt |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Orally disintegrating tablet
Adult Male Migraine Disorders Neurological disorder law.invention Randomized controlled trial law Oral administration medicine Humans Vasoconstrictor Agents Cross-Over Studies business.industry Sumatriptan Triazoles medicine.disease Crossover study Rizatriptan Tryptamines Serotonin Receptor Agonists Treatment Outcome Neurology Migraine Anesthesia Female Neurology (clinical) business medicine.drug Tablets |
| Zdroj: | Headache. 41(8) |
| ISSN: | 0017-8748 |
| Popis: | Objective.—To compare the proportion of patients who prefer rizatriptan orally disintegrating tablet (ODT) 10-mg to sumatriptan 50-mg tablet. Background.—Migraineurs express treatment preference based on a variety of attributes including the speed of pain relief and medication formulation. Rizatriptan ODT is an orally disintegrating formulation of rizatriptan, a selective 5-HT1B/1D receptor agonist. This study was conducted to determine patient preference between rizatriptan ODT 10-mg and sumatriptan 50-mg tablet for the acute treatment of migraine. Methods.—This was a multicenter, randomized, open-label, two-period crossover study conducted in the United States with 524 enrolled patients. Patients treated a single moderate or severe headache in each treatment period. Patients treated one migraine with either rizatriptan ODT 10-mg or sumatriptan 50-mg tablet, then treated a second migraine with the alternate therapy. Patients completed diary assessments at baseline, and 30, 45, 60, 90, and 120 minutes postdose and rated headache severity on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). At the final study visit following treatment of their second migraine, patients expressed preference for one of the two study medications by completing an interviewer-administered Global Preference Question and then responded to a self-administered series of questions to capture their most important reason for preferring one study medication over the other. Safety measurements were recorded through standard adverse experience reporting. Results.—Three hundred eighty-six patients treated two migraine attacks. For those patients who expressed a preference for either rizatriptan ODT or sumatriptan (n = 374), the percentage of patients who preferred rizatriptan ODT 10-mg (57%, n = 213) was significantly greater than those who preferred sumatriptan 50-mg tablet (43%, n = 161) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text